<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542552</url>
  </required_header>
  <id_info>
    <org_study_id>ONIMS</org_study_id>
    <nct_id>NCT03542552</nct_id>
  </id_info>
  <brief_title>Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa</brief_title>
  <official_title>Oral Nifedipine Versus Intravenous Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa: Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antepartum hemorrhage is defined as bleeding from or within the female genital tract,&#xD;
      occurring from 28+0 weeks of pregnancy and till delivery of the fetus. it occurs in 3-5% of&#xD;
      pregnancies and is an important cause of perinatal and maternal morbidity and mortality&#xD;
      worldwide&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are many tocolytic agents may have a role in conservative management of placenta previa&#xD;
      such as magnesium sulfate, calcium channel blockers and Î²-sympathormimetics. In 2004 Sharma&#xD;
      suggests that ritodrine hydrochloride in patients with symptomatic placenta previa tends to&#xD;
      prolong the pregnancy and result in an increase in birth weight of the babies without causing&#xD;
      any adverse effect on the mother and fetus&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The duration of prolongation of gestation</measure>
    <time_frame>1 month</time_frame>
    <description>measured from the time of enrollment to the time of delivery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Placenta Previa</condition>
  <arm_group>
    <arm_group_label>Nifidipne</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnisum sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion</description>
    <arm_group_label>Magnisum sulphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours</description>
    <arm_group_label>Nifidipne</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Estimated gestational age : between 28 weeks and 37 week's gestation&#xD;
&#xD;
          -  Confirmed Placenta previa; either major or minor degrees.&#xD;
&#xD;
          -  Placenta previa with preterm uterine contractions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe attack of bleeding requiring an immediate intervention.&#xD;
&#xD;
          -  Fetal heart rates instability or non-reassuring tracing&#xD;
&#xD;
          -  Intrauterine fetal death or major fetal anomalies.&#xD;
&#xD;
          -  If associated with abruptio placentae&#xD;
&#xD;
          -  Patients with known bleeding disorders or on anticoagulant therapy&#xD;
&#xD;
          -  Patients with severe medical disorders as myasthenia gravis documented magnesium&#xD;
             toxicity.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut university</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>ramy nasser</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
    <mesh_term>Placenta Previa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

